About Regentys
Regentys is a company based in Miami (United States) founded in 2009 by Marc Ramer, Rick Bulman, Gerard S Coombs, and Christine V Sapan was acquired by Generex Biotechnology in January 2019.. Regentys has raised $4.35 million across 6 funding rounds from investors including Generex Biotechnology and 43North. Regentys operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Miami, United States
- Founders Marc Ramer, Rick Bulman, Gerard S Coombs, Christine V Sapan
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.35 M (USD)
in 6 rounds
-
Latest Funding Round
$1.45 M (USD), Series A
Nov 07, 2016
-
Investors
Generex Biotechnology
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Generex Biotechnology
(Jan 07, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Regentys
Regentys has successfully raised a total of $4.35M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $1.45 million completed in November 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series A — $1.5M
-
First Round
First Round
(10 Jul 2009)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2016 | Amount | Series A - Regentys | Valuation |
investors |
|
| Jun, 2016 | Amount | Seed - Regentys | Valuation |
investors |
|
| May, 2016 | Amount | Series A - Regentys | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Regentys
Regentys has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Generex Biotechnology and 43North. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed-stage investments are targeted by 43North in startups.
|
Founded Year | Domain | Location | |
|
Technologies for large molecule drug delivery are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Regentys
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Regentys
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Regentys Comparisons
Competitors of Regentys
Regentys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for allergic and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Regentys
Frequently Asked Questions about Regentys
When was Regentys founded?
Regentys was founded in 2009.
Where is Regentys located?
Regentys is headquartered in Miami, United States. It is registered at Miami, Florida, United States.
Who is the current CEO of Regentys?
Rick Bulman is the current CEO of Regentys. They have also founded this company.
Is Regentys a funded company?
Regentys is a funded company, having raised a total of $4.35M across 6 funding rounds to date. The company's 1st funding round was a Series A of $1.2M, raised on Jul 10, 2009.
What does Regentys do?
Founded in 2009 and based in Miami, United States, focus is placed on the biotechnology sector through the development of regenerative therapies for gastrointestinal conditions. Operations center on the creation of Extracellular Matrix Hydrogel (ECMH), a porcine-derived product administered rectally to serve as a barrier and scaffold for mucosal repair in ulcerative colitis treatment. Leadership includes multiple co-founders guiding product advancement.
Who are the top competitors of Regentys?
Regentys's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Humacyte.
Who are Regentys's investors?
Regentys has 2 investors. Key investors include Generex Biotechnology, and 43North.